Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13992412 | 0.87 | SLC6A2 (0.42) | TAAR1SLC6A2OPRK1 | |
| SCHEMBL13992420 | 0.74 | — | — | |
| SCHEMBL14200043 | 0.74 | — | — | |
| SCHEMBL21288046 | 0.70 | ESR1 (0.38) | TAAR1SLC6A2ESR1ESR2SLC7A5 | |
| SCHEMBL13992416 | 0.70 | ESRRG (0.46) | ESR1ESR2MAPK1OPRK1OPRM1 | |
| SCHEMBL17931630 | 0.69 | MAOB (0.66) | SLC6A2SLC7A5OPRK1 | |
| SCHEMBL16552343 | 0.69 | MAOB (0.48) | TAAR1 | |
| SCHEMBL13619489 | 0.68 | — | — | |
| SCHEMBL6539282 | 0.68 | SLC7A5 (0.49) | TAAR1SLC6A2ESR1ESR2SLC7A5 | |
| SCHEMBL8980228 | 0.68 | CA2 (0.56) | ESR1ESR2MAPK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | ZUCKERMANN RONALD N | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | POLN, RNASE1, NCL | TAAR1 3767/4885SLC6A2 970/4885ESR1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.